CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 223 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01115231
NCT01115231N/ACompleted

Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration

VA Office of Research and Development·observational·Posted May 4, 2010·Updated Sep 30, 2019

In Brief

An observational study for Macular Degeneration. Completed, enrolled 223 participants across 2 sites.

Detailed Summary

Risk factors for Age-related Macular Degeneration (AMD) involves genetic variations in the alternative pathway of complement inhibitor factor H. The complement system is part of the innate and adaptive immune system. Smoking is the only environmental factor known to increase the risk of Age-related Macular Degeneration (AMD). Using serum samples of Age-related Macular Degeneration (AMD) patients and controls the investigators will test the hypothesis that smoking increases Age-related Macular Degeneration (AMD) by increasing complement activation; and that this is positively correlated with known disease variations in the complement factor H (CFH) gene.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 4, 2010
Enrollment StartOct 1, 2010
Primary CompletionJun 1, 2015
Study CompletionDec 31, 2016
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.2 years ago